India's HPCL seeks 10 LNG cargoes for March 2026-December 2027 delivery, sources say
HPCL is seeking one cargo per month for delivery in March, April, October and November in 2026, and in February, April, June, August, October and December in 2027, added one of the sources.
The tender closes on July 21.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
42 minutes ago
- Reuters
Pernod Ricard sells Imperial Blue whisky to India's Tilaknagar Industries
PARIS, July 23 (Reuters) - Pernod Ricard ( opens new tab said on Wednesday it agreed to sell its Imperial Blue whisky business division to Indian liquor maker Tilaknagar Industries ( opens new tab, as the French spirits maker boosts its focus on premium labels in its portfolio. The world's No. 2 Western spirits maker said that upon closing, the transaction, the amount of which has not been disclosed, was expected to be "immediately and meaningfully accretive" to Pernod Ricard India's operating margin and net sales growth rate. The transaction remains subject to approval from the competition commission of India, and closing is expected within the coming months, the statement said.
BBC News
42 minutes ago
- BBC News
Kimberly-Clark signs Barrow and Northfleet hydrogen contract
Tissue maker Kimberly-Clark has signed a £125m contract with two hydrogen facilities to reduce the amount natural gas used in its production lineThe Andrex and Kleenex producer signed a long-term deal receive hydrogen from the upcoming Carlton Power facility in Barrow-in-Furness, Cumbria, and the HYRO plant in Northfleet, Kent, which are expected to be operational in facilities have already secured funding and planning permission and will be built near existing Kimberly-Clark company said that, as a result of the deal, from 2027 it expected to see a 50% reduction to its 2024 consumption of natural gas across its UK production lines. The new facilities will produce and store hydrogen for the exclusive use of would replace fossil-fuel natural gas used for steam generation in the manufacture of toilet and facial tissues, the company said it expected construction on the plants to start in early 2026 and for the projects to be fully operational in the first half of added that the deals would help provide commercial security to the new for Barrow and Furness Michelle Scrogham said it was "great news for the area"."The Barrow hydrogen scheme is expected to employ around 200 people during its construction and around 10 people full-time once in operation," she comes as the government confirmed that a total of ten hydrogen projects it has helped fund across the country, including those in Barrow and Northfleet, had signed contracts and could proceed to becoming operational. Follow BBC Cumbria on X, Facebook, Nextdoor and Instagram.
Reuters
42 minutes ago
- Reuters
India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says
HYDERABAD July 23 (Reuters) - Dr Reddy's Laboratories ( opens new tab plans to launch a cheaper copycat version of Novo Nordisk's ( opens new tab blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday. Drugmakers are racing to get a share of the global obesity drug market, expected to generate around $150 billion in sales by the early 2030s, after Denmark-based Novo and its U.S. rival Eli Lilly (LLY.N), opens new tab saw extraordinary demand for their medicines. Dr Reddy's initially plans to launch the generic version of semaglutide - the active ingredient of Novo's Wegovy and diabetes medicine Ozempic - in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said. "U.S. and Europe will open later... (and) all the other Western markets will be open between 2029 to 2033," Israeli said a press conference to discuss the company's earnings. He expects the generic drug to generate 'hundreds of millions of dollars' in sales for the company. Semaglutide's patent is expected to expire in several countries next year, including in India in March. Novo Nordisk had sued Dr Reddy's in May alleging patent infringement of semaglutide, according to documents seen by Reuters. Dr Reddy's has filed relevant regulatory applications in all the countries it is planning to launch the generic version in, Israeli said. Other Indian drugmakers, including Cipla ( opens new tab, Lupin ( opens new tab, Biocon ( opens new tab, Sun Pharma ( opens new tab, also plan to launch these generic weight-loss drugs after Novo's and Lilly's success. Novo launched Wegovy in India last month, following Lilly's Mounjaro launch for weight-loss and diabetes management. The drugs belong to a class called GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer. Dr Reddy's also aims to launch 26 GLP-1 drugs within the next decade, Israeli said.
